HGFR/c-MET Antibody - Humanized, IgG4SP, (Research Grade emibetuzumab Biosimilar) - Low Endotoxin, Azide and BSA Free

Immobilized human c MET His at 2 ug/mL can bind HGFR/c-MET Antibody (emibetuzumab) - Humanized, IgG4SP, EC50=0.004797 ug/mL.

• Reactivity: Hu
• Applications: ELISA, Flow, Func
• Clonality: Monoclonal
• Host: Human
• Conjugate: Unconjugated
• Format: Low Endotoxin, Azide and BSA Free
• Concentration: LYOPH

HGFR/c-MET Antibody - Humanized, IgG4SP, (Research Grade emibetuzumab Biosimilar) - Low Endotoxin, Azide and BSA Free Summary

• Description: Expressed from CHO. The heavy chain type is huIgG4SP, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
  
  Also known as 'emibetuzumab'.
  
  IgG4SP is human IgG4 with S228P mutation.
  
  This product is shipped at ambient temperature. Upon receipt, store immediately at -20C or lower for 12 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: HGFR / c-Met
• Isotype: IgG4
• Clonality: Monoclonal
• Host: Human
• Gene: MET
• Purity: Protein A purified
• Endotoxin Note: < 0.001EU/ug,determined by LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA
  • Flow Cytometry
  • Functional

Packaging, Storage & Formulations

• Storage: Store at -20C in powder form. Store at -80C once reconstituted.
• Buffer: Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: Protein A purified
• Reconstitution Instructions: Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Alternate Names for Array

• AUTS9
• cMET
• c-MET
• EC 2.7.10
• EC 2.7.10.1
• hepatocyte growth factor receptor
• HGF R
• HGF receptor
• HGF/SF receptor
• HGFR
• Met (c-Met)
• met proto-oncogene (hepatocyte growth factor receptor)
• met proto-oncogene tyrosine kinase
• MET
• oncogene MET
• Proto-oncogene c-Met
• RCCP2
• Scatter factor receptor
• SF receptor
• Tyrosine-protein kinase Met

Background

Met is a receptor protein-tyrosine kinase (RPTK) for hepatocyte growth factor (HGF), which is a multifunctional cytokine controlling cell growth, morphogenesis, and motility. Met overexpression has been identified in a variety of human cancers (1). Met kinase domain possesses unique features that distinguish met from other members of the src family of protein tyrosine kinases. These results also demonstrate that the product of the activated met gene is a fusion protein and that the amino terminal end of this fusion protein exhibits homology to laminin B1 (2). Data suggest that RanBP9, functioning as an adaptor protein for the Met tyrosine kinase domain, can augment the HGF-Met signaling pathway and that RanBP9 overexpression may cause constitutive activation of the Ras signaling pathway (1). Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer Results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the Met protein and papillary renal carcinomas (3)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: MET
• Uniprot:
  • P08581()